Company intelligence / Profile preview

RevoluGen

Ascot, England, United Kingdomrevolugen.co.uk ↗

Ownership: Private
Development stage: Commercial

Overview

RevoluGen’s products enable rapid extraction of high molecular weight DNA with minimal small-fragment contamination. Their Fire Monkey NAIP technology improves long-read sequencing results and has broad application across all major sequencing platforms. The company’s technologies are used globally in population genomics, epidemiological studies, and microbial resistance monitoring. No clinical trial results as the company does not develop drugs or diagnostics.

Therapeutic areas: Other
Modalities: Device (Nucleic acid extraction kits)Molecular tools (for DNA extraction and purification)Not applicable to therapeutics; focuses on enabling technologies for genomics research
Industry: Non-Drug Biotech

Partnerships

Merck KGaAWelgeneCytivaTecanA4PLGC Biosearch Technologies

Beyond the preview

Go deeper on RevoluGen.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RevoluGen.

Explore the full profile